Funded Project Details - FY2021
|Title:|| Effectivenes, Safety, and Patient Preferences of Infliximab Biosimilar Medications for Inflammatory Bowel Disease|
Jason K. Hou
|Congressional District Code:
||Health Services R&D
|| February 2020 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Background: Biologic medications (biologics) are highly effective for diseases of the immune system, cancers, and other conditions; however, their high expense is a barrier to care and a burden to the healthcare system. Biologics cannot be exactly copied as “generic” medications. Biosimilars- similar, but not identical versions of biologic medications- are approved with large potential cost savings. However, VA providers and patients have concerns regarding biosimilar switching safety and effect...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.